Findings

What do systematic reviews say?

6 questions · 6 findings · 1 reviews · Kidney and Transplant

No studies found 1 · 16.7%GRADE not reported 0 · 0%Very low 0 · 0%Low 5 · 83.3%Moderate 0 · 0%High 0 · 0%

Death · patients on HD with HCV infection

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Relapse Number of participants having recurrence after stopping · patients on HD with HCV infection

Pegylated interferon plus ribavirin may leads to lower relapse(recurrence after stopping) compared with pegylated interferon alone (low certainty).

1 finding from 1 review

Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
RR 0.33 [0.23, 0.48]
1 study · 377 participants
Low

End‐of‐treatment response · patients on HD with HCV infection

Pegylated interferon plus ribavirin showed no clear difference in end‐of‐treatment response compared with pegylated interferon alone (low certainty).

1 finding from 1 review

Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
RR 1.01 [0.94, 1.09]
1 study · 377 participants
Low

Sustained virological response · patients on HD with HCV infection

Pegylated interferon plus ribavirin may leads to higher sustained virological response compared with pegylated interferon alone (low certainty).

1 finding from 1 review

Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
RR 1.8 [1.46, 2.21]
1 study · 377 participants
Low

Treatment discontinuation · patients on HD with HCV infection

Pegylated interferon plus ribavirin showed no clear difference in treatment discontinuation compared with pegylated interferon alone (low certainty).

1 finding from 1 review

Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
RR 1.71 [0.69, 4.24]
1 study · 377 participants
Low

Adverse events · patients on HD with HCV infection

Pegylated interferon plus ribavirin may leads to higher adverse events compared with pegylated interferon alone (low certainty).

1 finding from 1 review

Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
RR 1.1 [1.01, 1.19]
1 study · 377 participants
Low